Filter
704
Filtered Results: 704
Text search:
Drug
Prevention
and
Information
Programme
of
the
European
Union
Featured
Recommendations
53
New Publications
150
Language
Document type
No document type
419
Studies & Reports
146
Guidelines
65
Manuals
32
Strategic & Response Plan
23
Fact sheets
9
Situation Updates
5
Training Material
4
Resource Platforms
1
Countries / Regions
Western and Central Europe
75
Eastern Europe
29
Global
26
Sierra Leone
18
Myanmar / Burma
16
Ukraine
15
India
12
Zambia
12
Africa
12
Liberia
11
Kenya
11
Uganda
8
Nigeria
7
Bangladesh
7
Malawi
7
Eastern Europe and Central Asia
7
Lesotho
6
Tajikistan
6
Senegal
5
Ethiopia
5
South Africa
5
Latin America and the Carribbean
5
Guinea
4
Ghana
4
Philippines
4
Nepal
4
Tanzania
4
Cambodia
4
Rwanda
4
Namibia
4
Eswatini/ Swaziland
4
Middle East and North Africa
4
Asia
4
Russia
4
Thailand
3
Botswana
3
West and Central Africa
3
Albania
3
Laos
3
Moldova
3
Georgia
3
Burkina Faso
2
Zimbabwe
2
South Sudan
2
Germany
2
North Macedonia
2
East and Southern Africa
2
Vietnam
2
Congo, Democratic Republic of
1
USA
1
Somalia
1
Pakistan
1
Iraq
1
Afghanistan
1
Turkey
1
Syria
1
Indonesia
1
Ireland
1
Sudan
1
Benin
1
Brazil
1
Serbia
1
El Salvador
1
Sri Lanka
1
South–East Asia Region
1
Western Pacific Region
1
Bhutan
1
Venezuela
1
Poland
1
Armenia
1
Bulgaria
1
Estonia
1
Romania
1
Lithuania
1
Uzbekistan
1
Kazakhstan
1
Turkmenistan
1
Denmark
1
Belarus
1
Authors & Publishers
Publication Years
Category
Countries
173
Clinical Guidelines
57
Public Health
46
Pharmacy & Technologies
19
Key Resources
13
Women & Child Health
10
Capacity Building
5
Toolboxes
HIV
117
TB
117
Mental Health
90
AMR
60
COVID-19
26
Pharmacy
23
Rapid Response
19
Refugee
15
Planetary Health
14
NCDs
14
Ebola
13
Global Health Education
10
Disability
9
Conflict
9
Caregiver
7
NTDs
7
Health Financing Toolbox
7
Polio
3
Natural Hazards
2
Cholera
1
Zika
1
Specific Hazards
1
Social Ethics
1
Health Financing
1
22 Sept. 2021
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in t... darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisive role in restricting fair access to a life-saving health product. This report focuses on six leading vaccine developers, AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.
Available in Arabic, English, French, German and Spanish
Sepsis contributes significantly to preventable mortality and is the final common pathway to death for severe infectious diseases; it can also arise as a complication ... injuries and non-communicable diseases.
The sixteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Disea...
Experiences from Indonesia, Kenya, Uganda and Ukraine
Afr J Thoracic Crit Care Med 2021;27(4):Published online 22 October 2021. https://doi.org/10.7196/AJTCCM.2021.v27i4.173
Report of the Joint World Health Organization–Brien Holden Vision Institute Global Scientific Meeting on Myopia | University of New South Wales,...
The Lancet. Published Online December 22, 2016 http://dx.doi.org/10.1016/S0140-6736(16)32621-6. Open Access
World's largest Science, Technology & Medicine Open Access book publisher
Chapter 7 from the book People's Movements in the 21st Century - Risks, Challenges ... Benefits
PLOS ONE | https://doi.org/10.1371/journal.pone.0203986 October 3, 2018
The Road to Recovery. This synthesis report is based on three national studies on the evolution of the... Ebola epidemic and its impact on Guinea, Liberia and Sierra Leone
Improving the quality of hospital antibiotic use is a major goal of WHO’s global action plan to combat antimicrobial resistance. ... WHO Essential Medicines List Access, Watch, and Reserve (AWaRe) classification could facilitate simple stewardship interventions that are widely applicable globally. We aimed to present data on patterns of paediatric AWaRe antibiotic use that could be used for local and national stewardship interventions.
www.thelancet.com/lancetgh Vol 7 July 2019
Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493
.Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly ... cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mechanisms underlying Trypanosoma cruzi’s infection and the host-parasite interactions that follow, prompt diagnosis and treatment remain a challenge, particu-larly in developing countries and also in those where the disease is considered non-endemic. This review intends to present an up-to-date review of the parasite’s life cycle, genetic diversity, virulence factors, and infective mechanisms, as well as the epidemiology, clinical presentation, diagnosis, and treatment options of the main chronic complications of Chagas disease.
The Global guidance framework for the responsible use of the life sciences: mitigating biorisks ...
An action research conducted in Bang Shau village Northern Shan State, Myanmar
The report underscores that sexual and reproductive health and rights are often the first to be ...
Improvements in water sanitation and hygiene (WASH) and wastewater management in all sectors are critical elements of preventing infections ... reducing the spread of antimicrobial resistance (AMR) as identified in the Global Action Plan to combat AMR. Yet, at present, WASH and wastewater management actors and improvement actions are under-represented in AMR multi-stakeholder platforms and national action plans (NAPs). This WHO/FAO/OIE technical brief on WASH and wastewater management to reduce the spread of AMR provides a summary of evidence and rationale for WASH and wastewater actions within AMR NAPs and sector specific policy to combat AMR. Evidence and actions are presented in the domains of; coordination and leadership, households and communities, health care facilities, animal and plant production, manufacturing of antimicrobials, and surveillance and research.
